PMDA drug package insert
リブタヨ点滴静注350mg
PMDA Prescription drug · リジェネロン・ジャパン株式会社 · package insert Sep 30, 2026
Key facts
| Brand names | リブタヨ点滴静注350mg |
|---|---|
| Nonproprietary names | セミプリマブ（遺伝子組換え） |
| Companies | 製造販売元／リジェネロン・ジャパン株式会社 |
| Product type | Prescription drug |
| Therapeutic category | 抗悪性腫瘍剤 ヒト型抗ヒトPD-1モノクローナル抗体 |
| Therapeutic category codes | 874291 |
| YJ codes | 4291466A1024 |
| Approval numbers | 30400AMX00458 |
| Package insert edition | 第13版 |
| Package insert date | Sep 30, 2026 |
| PMDA document key | 850555_4291466A1024_2 |
| PMDA company code | 850555 |
At a glance
- 1–9 Package insert revisions
- 10–99 Related PMDA documents
- None Safety communications
- Yes PMDA review report published
- Yes Risk management plan (RMP)
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About PMDA approved drugs and package inserts (Japan)
Japan's PMDA publishes the package insert (添付文書) of every prescription drug, OTC drug and regenerative medical product, with brand and nonproprietary names, YJ codes and approval numbers. Names appear in Japanese as published.
Source: Pharmaceuticals and Medical Devices Agency (PMDA), Japan, package insert database · Source date: